Join the Nonalcoholic Fatty Liver Disease group to help and get support from people like you.
Nonalcoholic Fatty Liver Disease News
Related terms: Nonalcoholic Steatohepatitis, Idiopathic Fatty Liver, Steatosis, Steatohepatitis, Fatty Liver, NASH, NAFLD, MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Ozempic Can Treat Fatty Liver Disease
THURSDAY, May 1, 2025 – The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has found. Nearly twice as many people taking semaglutide...
Blood Test Can Predict Fatty Liver Disease
FRIDAY, April 25, 2025 – Doctors can accurately predict a person’s risk of fatty liver disease as early as 16 years before symptoms develop, a new study says. A blood test looking for five specific p...
DDW: Certain Proteins Predict Metabolic Dysfunction-Associated Steatotic Liver Disease
FRIDAY, April 25, 2025 – Five proteins are significant predictors of metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study presented at the 2025 Digestive Disease...
'Broken' Sleep Could Be Hallmark of Obesity-Linked Liver Disease
THURSDAY, Dec. 5, 2024 – Fatty liver disease may contribute to fragmented sleep patterns, robbing already sick people of good rest, a new study finds. These folks woke up more often in the night,...
AI Algorithm Can ID Metabolic Dysfunction-Associated Steatotic Liver Disease
WEDNESDAY, Nov. 27, 2024 – An algorithm can identify individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) with about 88 percent accuracy using electronic medical record...
AI Helps Spot Liver Disease Early
MONDAY, Nov. 18, 2024 – AI can help doctors diagnose early cases of fatty liver disease, a new study says. An AI program trained to spot a leading type of the disease, called metabolic-associated...
Fatty Liver Disease Now Affects 4 in 10 U.S. Adults
WEDNESDAY, Nov. 13, 2024 – Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns. By 2018, federal data showed that 42% of...
GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, Diabetes
TUESDAY, Sept. 17, 2024 – For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with...
New Definition of Steatotic Liver Disease Improves Prediction of Kidney Disease
TUESDAY, Aug. 20, 2024 – Using a new classification of steatotic liver disease (SLD) based on the presence of metabolic dysfunction and alcohol consumption, metabolic dysfunction-associated...
Study Reveals MASLD, MetALD Responsible for One-Third of ICU Cirrhosis Cases
TUESDAY, Aug. 6, 2024 – Metabolic dysfunction-associated steatotic liver disease (MASLD)-related and metabolic and alcohol-related liver disease (MetALD)-related cirrhosis is responsible for...
Facial Temperatures Might Help Docs Diagnose Diabetes, Fatty Liver Disease
WEDNESDAY, July 3, 2024 – Screening for chronic illnesses like diabetes or fatty liver disease could one day be as simple as checking the temperature of your nose, eyes or cheeks. The temperature of...
Survodutide Tied to Significant Improvement in Fatty Liver Disease
MONDAY, June 17, 2024 – Most patients taking survodutide, a dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor, experience significant improvement in metabolic...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for...
Experimental GLP-1 Med Might Be Breakthrough Against Fatty Liver Disease
MONDAY, June 10, 2024 – An experimental 'supercharged' form of popular GLP-1 weight-loss meds could help ease fatty liver disease, a new trial suggests. The drug under development, survodutide,...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...